Investigational drug · Phase 2
Letetresgene autoleucel
Also called: lete-cel, GSK3377794
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Neoplasms.
Phase 2Last checked: Nov 20, 2026Latest source record: Aug 11, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
7
Any phase or sponsor naming "Letetresgene autoleucel"
First trial start
2019
Dec 31, 2019
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Letetresgene autoleucel", any sponsor or status.
Conditions studied
As listed on its trial records.
- Neoplasms
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Letetresgene autoleucel" as an intervention, largest first.
- Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid TumorsActive, not recruiting
USWM CT, LLCIndustry
NCT03967223 · 103 participants · Start Dec 31, 2019 · Primary completion Mar 1, 2024
Drug: Letetresgene autoleucel (lete-cel, GSK3377794); Fludarabine and 1 more · For: Neoplasms
Sites: Duarte, California; Stanford, California; Denver, Colorado · 38 sites in all
USWM CT, LLCIndustry
NCT06703346 · 82 participants · Start Dec 31, 2019 · Primary completion Mar 1, 2024
Drug: Letetresgene autoleucel (Lete-Cel (GSK3377794)); Cyclophosphamide and 1 more · For: Neoplasms
Sites: Duarte, California; Stanford, California; Denver, Colorado · 38 sites in all
GlaxoSmithKlineGSK (GSK)
NCT03709706 · 34 participants · Start Dec 31, 2018 · Primary completion Jun 27, 2022
Drug: Lete-cel; Pembrolizumab · For: Neoplasms
Sites: Duarte, California; La Jolla, California; Sacramento, California · 31 sites in all
GlaxoSmithKlineGSK (GSK)
NCT02992743 · 23 participants · Start Dec 6, 2016 · Primary completion Nov 1, 2021
Drug: letetresgene autoleucel (GSK3377794); Cyclophosphamide and 1 more · For: Neoplasms
Sites: Tampa, Florida; Ann Arbor, Michigan; St Louis, Missouri · 6 sites in all
GlaxoSmithKlineGSK (GSK)
NCT02588612 · 10 participants · Start Feb 1, 2016 · Primary completion Aug 10, 2020
Drug: letetresgene autoleucel (GSK3377794); Cyclophosphamide and 1 more · For: Neoplasms
Sites: Miami, Florida; Tampa, Florida; Houston, Texas
USWM, LLC (dba US WorldMeds)Industry
NCT05993299 · 7 participants · Start Dec 31, 2019 · Primary completion Oct 12, 2022
Drug: Letetresgene autoleucel; Cyclophosphamide and 1 more · For: Neoplasms
Sites: Duarte, California; Stanford, California; Denver, Colorado · 38 sites in all
GlaxoSmithKlineGSK (GSK)
NCT03168438 · 6 participants · Start Aug 18, 2017 · Primary completion Jul 13, 2020
Drug: Letetresgene autoleucel; Letetresgene autoleucel with pembrolizumab and 3 more · For: Neoplasms
Sites: Duarte, California; Miami, Florida; Tampa, Florida · 5 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- The Landscape of Clinical Trials for TCR-T Cell Therapy.
Fan X, Yu T, Liao Q, et al. · Am J Clin Oncol 2026
- Letetresgene autoleucel in advanced non-small cell lung cancer: a step towards truly personalized immunotherapy?
Molina-Pérez MA, Martínez-Recio S, Barba A, et al. · Transl Lung Cancer Res 2025
- Adoptive T-Cell Therapy in Sarcomas.
Kucharczyk M, Hatipoglu E, Jones RL, et al. · Curr Oncol Rep 2025
- NY-ESO-1 targeting in non-small cell lung cancer: promise and challenges of letetresgene autoleucel.
Monaca F, Gómez-Randulfe I, Califano R · Transl Lung Cancer Res 2025
- Letetresgene Autoleucel: A Milestone in Treatment of Myxoid/Round Cell Liposarcoma.
Hatipoglu E, Furness AJS, Jones RL · J Clin Oncol 2025
- Letetresgene Autoleucel in Advanced/Metastatic Myxoid/Round Cell Liposarcoma.
D'Angelo SP, Druta M, Van Tine BA, et al. · J Clin Oncol 2025
Also in development for Neoplasms
- CetrelimabJNJ-63723283Phase 38 trials
Johnson & Johnson (Janssen) · Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Neoplasms
- VT3989Phase 32 trials
Vivace Therapeutics, Inc · Pleural Mesothelioma, Mesothelioma, Solid Tumor, Adult
- [177Lu]Lu-NeoBLutetium NeoB, [177Lu]-NeoBPhase 22 trials
Novartis · Breast Cancer, Neoplasms
- [68Ga]Ga-NeoBGallium NeoB, [68Ga]-NeoBPhase 22 trials
Novartis · Breast Cancer, Neoplasms
- Checkpoint InhibitorPhase 22 trials
EpicentRx, Inc. · Solid Tumor, Adult, Cancer, Neoplasms
- LY188011Phase 22 trials
Eli Lilly · Neoplasms, Child, Adolescent
- AdAPT-001Phase 21 trial
EpicentRx, Inc. · Solid Tumor, Adult, Cancer, Neoplasms
- CORT125236NenocorilantPhase 21 trial
Corcept Therapeutics · Neoplasms
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.